- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Baxter issues recall of antibiotic IV bags after bits of cardboard flagged in solution | ||
| Di | GSK CEO targets $2.5B in cost savings from mature products, procurement, supply chain | ||
| Di | Havas Lynx revamps New York C-suite 16 months after last shakeup | ||
| 27.07. | FDA approves Otsuka's ADHD drug Simtriyo, teeing up its 'next major CNS launch' | ||
| 27.07. | On 4th try, Outlook Therapeutics scores FDA nod for reformulated version of Roche's Avastin for AMD | ||
| 27.07. | Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter | ||
| 27.07. | AstraZeneca stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss | ||
| 27.07. | Legend Biotech CEO abruptly steps down without permanent replacement | ||
| 24.07. | Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey | ||
| 24.07. | Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback | ||
| 24.07. | Novo escalates Lilly false advertising suit with planned bid to halt comparative ads | ||
| 24.07. | Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial | ||
| 24.07. | Amgen hands in data package in hopes of FDA hearing for Tavneos defense | ||
| 24.07. | Merck stages expanded access to monthly HIV PrEP pill ahead of approval | ||
| 24.07. | GSK's first lung cancer approval, a new IPO path and more | ||
| 23.07. | In FDA compounding adcomm, advisers urge against restrictions on 1st of 7 peptides | ||
| 23.07. | Roche defends 6B franc Vabysmo peak sales target despite another quarterly miss | ||
| 23.07. | BeOne jumps aboard onshoring train with $300M to add small molecule production in US | ||
| 23.07. | FDA rebukes 2 Indian API plants over data controls, sanitation issues | ||
| 22.07. | GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal | ||
| 22.07. | FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV | ||
| 22.07. | What to Expect at PODD 2026 | ||
| 22.07. | Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data | ||
| 22.07. | Trump floats countdown to 200% tariffs on generic drugs imported to US | ||
| 22.07. | Summit Therapeutics updates ivonescimab survival data ahead of FDA decision date |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.